ArticleAnnals of translational medicine2021
Phosphorylated nuclear factor erythroid 2-related factor 2 promotes the secretion of C-C motif chemokine ligand 2 and the recruitment of M2 macrophages.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 16 citations in OpenAlex.
- Transcriptional Repression of CCL2 by KInternational journal of molecular sciences · 2025Article
- Erratum to Phosphorylated nuclear factor erythroid 2-related factor 2 promotes the secretion of C-C motif chemokine ligand 2 and the recruitment of M2 macrophages.Annals of translational medicine · 2025Article
- The interplay between T lymphocytes and macrophages in myocardial ischemia/reperfusion injury.Molecular and cellular biochemistry · 2024Review
- Platelet membrane-camouflaged nanoparticles carry microRNA inhibitor against myocardial ischaemia‒reperfusion injury.Journal of nanobiotechnology · 2022Article
- Sedentary Lifestyles and a Hypercaloric Diets During Middle Age, are Binomial Conducive to Fatal Progression, That is Counteracted by the Hormetic Treatment of Exercise, Metformin, and Tert-Butyl Hydroquinone: An Analysis of Female Middle-Aged Rat Liver Mitochondria.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNuclear factor erythroid 2-related factor 2 (Nrf2) has been shown to ameliorate early ischemia-reperfusion (I/R) injury after activation by tertiary butylhydroquinone (TBHQ). However, despite macrophage-associated inflammation being a distinguishing feature of I/R injury, the precise roles and mechanisms of Nrf2 in macrophage-associated inflammation are still poorly understood.
methodsI/R and hypoxia/reperfusion (H/R) models were constructed
resultsThe Nrf2 activator, TBHQ, induced phosphorylation of Nrf2 and promoted the secretion of Ccl2 by myocardial microvascular endothelial cells. The secreted Ccl2 induced the chemotaxis of M2 macrophages into the injury site and triggered the secretion of anti-inflammatory factors including interleukin (IL)-10 and tumor growth factor (TGF)-β1 by M2 macrophages, thereby reducing early myocardial ischemia reperfusion injury (MI/R).
conclusionsActivation of Nrf2 alleviated oxidative stress during myocardial ischemia and reperfusion by inducing the secretion of anti-inflammatory factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.